Title: C-reactive protein is associated with postoperative outcomes in patients with intestinal
Behçet’s disease
Version: 1 Date: 13 Apr 2021
Reviewer's report:
Major points
1. Some intestinal BD cases that did not meet the ISG criteria were included as "suspected cases",
but analysis with only cases that met the criteria should also be included in the analysis.
2.  Authors stated "Surgeries not associated with intestinal lesions were excluded", but a
flowchart should be provided to show how many cases were screened and how many cases were
included in the analysis.
3. the definition of "CRP within 5 days after surgery" is ambiguous. There is a wide range from
1 to 5 days postoperatively, and the numerical value of CRP fluctuates greatly, so the number
of days should be strictly determined and evaluated.
4. The overall disease activity of Behcet's disease at the time of surgery may be more important
than CRP alone, and should evaluate the relationship between overall activity such as BDCAF
and rate of relapse.
5. Recently, the use of TNF antibodies has reduced the number of surgical cases in intestinal
Behcet's disease, but is there a change over time? Has there been a change over time? Is there
a possibility of preventing relapse by using TNF?
Minor points
1. Some references are missing (page 4 line 83, page 10, line 209, etc.)
2. The title of the paper needs to be changed, as it is not possible to determine predictors based
on retrospective studies. Rather, the term "associate" would be better.
3. Table 1 should also include other types of Behcet's disease phenotypes such as skin
manifestations, oral ulcers, genital ulcers, eye, HLA-B*51, etc.  "immunomodulator" should
include specific agents used for the treatments.
Title: C-reactive protein is associated with postoperative outcomes in patients with intestinal
Behçet’s disease
Version: 1 Date: 13 Apr 2021
Reviewer's report:
Major points
1. Some intestinal BD cases that did not meet the ISG criteria were included as "suspected cases",
but analysis with only cases that met the criteria should also be included in the analysis.
2.  Authors stated "Surgeries not associated with intestinal lesions were excluded", but a
flowchart should be provided to show how many cases were screened and how many cases were
included in the analysis.
3. the definition of "CRP within 5 days after surgery" is ambiguous. There is a wide range from
1 to 5 days postoperatively, and the numerical value of CRP fluctuates greatly, so the number
of days should be strictly determined and evaluated.
4. The overall disease activity of Behcet's disease at the time of surgery may be more important
than CRP alone, and should evaluate the relationship between overall activity such as BDCAF
and rate of relapse.
5. Recently, the use of TNF antibodies has reduced the number of surgical cases in intestinal
Behcet's disease, but is there a change over time? Has there been a change over time? Is there
a possibility of preventing relapse by using TNF?
Minor points
1. Some references are missing (page 4 line 83, page 10, line 209, etc.)
2. The title of the paper needs to be changed, as it is not possible to determine predictors based
on retrospective studies. Rather, the term "associate" would be better.
3. Table 1 should also include other types of Behcet's disease phenotypes such as skin
manifestations, oral ulcers, genital ulcers, eye, HLA-B*51, etc.  "immunomodulator" should
include specific agents used for the treatments.
Please review this paper.
user
Title: C-reactive protein is associated with postoperative outcomes in patients with intestinal
Behçet’s disease
Version: 1 Date: 13 Apr 2021
Reviewer's report:
Major points
1. Some intestinal BD cases that did not meet the ISG criteria were included as "suspected cases",
but analysis with only cases that met the criteria should also be included in the analysis.
2.  Authors stated "Surgeries not associated with intestinal lesions were excluded", but a
flowchart should be provided to show how many cases were screened and how many cases were
included in the analysis.
3. the definition of "CRP within 5 days after surgery" is ambiguous. There is a wide range from
1 to 5 days postoperatively, and the numerical value of CRP fluctuates greatly, so the number
of days should be strictly determined and evaluated.
4. The overall disease activity of Behcet's disease at the time of surgery may be more important
than CRP alone, and should evaluate the relationship between overall activity such as BDCAF
and rate of relapse.
5. Recently, the use of TNF antibodies has reduced the number of surgical cases in intestinal
Behcet's disease, but is there a change over time? Has there been a change over time? Is there
a possibility of preventing relapse by using TNF?
Minor points
1. Some references are missing (page 4 line 83, page 10, line 209, etc.)
2. The title of the paper needs to be changed, as it is not possible to determine predictors based
on retrospective studies. Rather, the term "associate" would be better.
3. Table 1 should also include other types of Behcet's disease phenotypes such as skin
manifestations, oral ulcers, genital ulcers, eye, HLA-B*51, etc.  "immunomodulator" should
include specific agents used for the treatments.
assistant